Mennini FS, Paoletti M, Bini C, Marcellusi A, Falcone M, Andreoni M. Cost-utility analysis of ceftolozane/tazobactam vs meropenem in patients with hospital-acquired pneumonia (HABP) or ventilator-associated pneumonia (VABP). Grhta [Internet]. 2022 Apr. 7 [cited 2024 Nov. 21];9(1):45-57. Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/2287